← Back to patent-cliff list
Mitoquinone mesylate
Tier C — Watch / tradeMitoquinone mesylate
Antipodean
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HIF1A
Indications (approved)：Schizophrenia, Cognitive impairment, 线粒体疾病, 脆弱, 健康老龄化, Mild cognitive impairment, COVID-19, Respiratory tract infection
Regional status
US
Phase III
2024-06-01
EU
Phase III
2024-06-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Mitoquinone mesylate?
Approved indications include: Schizophrenia, Cognitive impairment, 线粒体疾病, 脆弱, 健康老龄化, Mild cognitive impairment, COVID-19, Respiratory tract infection.
When does the Mitoquinone mesylate patent expire?
No public expiry year is available for Mitoquinone mesylate yet; this page updates once verified.
How do I get a quote for Mitoquinone mesylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01